Class information for: |
Basic class information |
| Class id | #P | Avg. number of references |
Database coverage of references |
|---|---|---|---|
| 23991 | 327 | 25.5 | 80% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
| 317 | 3 | HER2//TRASTUZUMAB//CHRONIC MYELOID LEUKEMIA | 39408 |
| 1452 | 2 | CHRONIC MYELOID LEUKEMIA//IMATINIB//NILOTINIB | 7818 |
| 23991 | 1 | REGORAFENIB//N DESETHYL SUNITINIB//N DESMETHYL IMATINIB | 327 |
Terms with highest relevance score |
| rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|---|
| 1 | REGORAFENIB | authKW | 853606 | 11% | 26% | 35 |
| 2 | N DESETHYL SUNITINIB | authKW | 373519 | 1% | 100% | 4 |
| 3 | N DESMETHYL IMATINIB | authKW | 351963 | 2% | 54% | 7 |
| 4 | SORAFENIB N OXIDE | authKW | 210103 | 1% | 75% | 3 |
| 5 | ANTICANCER TARGETED THERAPY | authKW | 186759 | 1% | 100% | 2 |
| 6 | MULTIKINASE INHIBITOR | authKW | 148294 | 3% | 18% | 9 |
| 7 | O DESMETHYL GEFITINIB | authKW | 124505 | 1% | 67% | 2 |
| 8 | CGP74588 | authKW | 122861 | 2% | 26% | 5 |
| 9 | ADVERSE EVENT PROPHYLAXIS | authKW | 93380 | 0% | 100% | 1 |
| 10 | AMIDE HYDROLYSIS PRODUCT | authKW | 93380 | 0% | 100% | 1 |
Web of Science journal categories |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | Chemistry, Analytical | 4248 | 49% | 0% | 159 |
| 2 | Biochemical Research Methods | 3181 | 33% | 0% | 108 |
| 3 | Pharmacology & Pharmacy | 1350 | 38% | 0% | 125 |
| 4 | Oncology | 203 | 15% | 0% | 48 |
| 5 | Medical Laboratory Technology | 195 | 4% | 0% | 14 |
| 6 | Toxicology | 45 | 4% | 0% | 14 |
| 7 | Chemistry, Medicinal | 14 | 3% | 0% | 9 |
| 8 | Electrochemistry | 10 | 2% | 0% | 7 |
| 9 | Chemistry, Multidisciplinary | 7 | 6% | 0% | 21 |
| 10 | Biochemistry & Molecular Biology | 4 | 8% | 0% | 26 |
Address terms |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | BIOANAL METAB PHAMACOKINET | 93380 | 0% | 100% | 1 |
| 2 | BIOL SCI ENGN PROGRAM | 93380 | 0% | 100% | 1 |
| 3 | CANC ISTANCE EXPLORING TARGETING | 93380 | 0% | 100% | 1 |
| 4 | CH COCHIN HOTEL DIEU BROCA | 93380 | 0% | 100% | 1 |
| 5 | COORDONNE ONCOL AMBULATOIRE | 93380 | 0% | 100% | 1 |
| 6 | CREAT EA 3846 | 93380 | 0% | 100% | 1 |
| 7 | DISCOVERY CHEM SYNTH RADIOCHEM | 93380 | 0% | 100% | 1 |
| 8 | DRUG BIOAVAI IL UNITE | 93380 | 0% | 100% | 1 |
| 9 | GASTROINTESTINAL LIVER ONCOL UNIT | 93380 | 0% | 100% | 1 |
| 10 | HEMATO ONCOLOGY | 93380 | 0% | 100% | 1 |
Journals |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | LATIN AMERICAN JOURNAL OF PHARMACY | 24117 | 8% | 1% | 25 |
| 2 | JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 17967 | 15% | 0% | 48 |
| 3 | BIOMEDICAL CHROMATOGRAPHY | 7661 | 5% | 0% | 17 |
| 4 | JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | 5757 | 8% | 0% | 26 |
| 5 | TARGETED ONCOLOGY | 2029 | 1% | 1% | 3 |
| 6 | JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES | 1690 | 3% | 0% | 9 |
| 7 | THERAPEUTIC DRUG MONITORING | 1588 | 2% | 0% | 8 |
| 8 | ACTA CHROMATOGRAPHICA | 1332 | 1% | 0% | 3 |
| 9 | JOURNAL OF CHROMATOGRAPHIC SCIENCE | 1101 | 2% | 0% | 7 |
| 10 | BIOANALYSIS | 1065 | 1% | 0% | 4 |
Author Key Words |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | REGORAFENIB | 853606 | 11% | 26% | 35 | Search REGORAFENIB | Search REGORAFENIB |
| 2 | N DESETHYL SUNITINIB | 373519 | 1% | 100% | 4 | Search N+DESETHYL+SUNITINIB | Search N+DESETHYL+SUNITINIB |
| 3 | N DESMETHYL IMATINIB | 351963 | 2% | 54% | 7 | Search N+DESMETHYL+IMATINIB | Search N+DESMETHYL+IMATINIB |
| 4 | SORAFENIB N OXIDE | 210103 | 1% | 75% | 3 | Search SORAFENIB+N+OXIDE | Search SORAFENIB+N+OXIDE |
| 5 | ANTICANCER TARGETED THERAPY | 186759 | 1% | 100% | 2 | Search ANTICANCER+TARGETED+THERAPY | Search ANTICANCER+TARGETED+THERAPY |
| 6 | MULTIKINASE INHIBITOR | 148294 | 3% | 18% | 9 | Search MULTIKINASE+INHIBITOR | Search MULTIKINASE+INHIBITOR |
| 7 | O DESMETHYL GEFITINIB | 124505 | 1% | 67% | 2 | Search O+DESMETHYL+GEFITINIB | Search O+DESMETHYL+GEFITINIB |
| 8 | CGP74588 | 122861 | 2% | 26% | 5 | Search CGP74588 | Search CGP74588 |
| 9 | ADVERSE EVENT PROPHYLAXIS | 93380 | 0% | 100% | 1 | Search ADVERSE+EVENT+PROPHYLAXIS | Search ADVERSE+EVENT+PROPHYLAXIS |
| 10 | AMIDE HYDROLYSIS PRODUCT | 93380 | 0% | 100% | 1 | Search AMIDE+HYDROLYSIS+PRODUCT | Search AMIDE+HYDROLYSIS+PRODUCT |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
| Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
|---|---|---|---|---|
| 1 | HERVIOU, P , THIVAT, E , RICHARD, D , ROCHE, L , DOHOU, J , POUGET, M , ESCHALIER, A , DURANDO, X , AUTHIER, N , (2016) THERAPEUTIC DRUG MONITORING AND TYROSINE KINASE INHIBITORS.ONCOLOGY LETTERS. VOL. 12. ISSUE 2. P. 1223 -1232 | 43 | 51% | 1 |
| 2 | ROOD, JJM , SCHELLENS, JHM , BEIJNEN, JH , SPARIDANS, RW , (2016) RECENT DEVELOPMENTS IN THE CHROMATOGRAPHIC BIOANALYSIS OF APPROVED KINASE INHIBITOR DRUGS IN ONCOLOGY.JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS. VOL. 130. ISSUE . P. 244 -263 | 62 | 38% | 0 |
| 3 | SHARMA, K , SURESH, PS , MULLANGI, R , SRINIVAS, NR , (2015) QUANTITATION OF VEGFR2 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR) INHIBITORS - REVIEW OF ASSAY METHODOLOGIES AND PERSPECTIVES.BIOMEDICAL CHROMATOGRAPHY. VOL. 29. ISSUE 6. P. 803 -834 | 25 | 68% | 0 |
| 4 | ALY, FA , ALANAZY, HD , (2012) KINETIC SPECTROPHOTOMETRIC METHODS FOR THE DETERMINATION OF IMATINIB MESYLATE IN PURE AND TABLET DOSAGE FORM.ASIAN JOURNAL OF CHEMISTRY. VOL. 24. ISSUE 12. P. 5511-5514 | 16 | 100% | 0 |
| 5 | AJIMURA, TO , BORGES, KB , FERREIRA, AF , DE CASTRO, FA , DE GAITANI, CM , (2011) CAPILLARY ELECTROPHORESIS METHOD FOR PLASMATIC DETERMINATION OF IMATINIB MESYLATE IN CHRONIC MYELOID LEUKEMIA PATIENTS.ELECTROPHORESIS. VOL. 32. ISSUE 14. P. 1885 -1892 | 21 | 72% | 8 |
| 6 | ZHANG, Y , YUAN, RR , ZHENG, XK , HUA, CL , WANG, YQ , (2016) VALIDATED UPLC-MS/MS METHOD FOR THE DETERMINATION OF SUNITINIB IN RAT PLASMA.LATIN AMERICAN JOURNAL OF PHARMACY. VOL. 35. ISSUE 6. P. 1304 -1308 | 16 | 80% | 0 |
| 7 | SPARIDANS, RW , IUSUF, D , SCHINKEL, AH , SCHELLENS, JHM , BEIJNEN, JH , (2009) LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRIC ASSAY FOR THE LIGHT SENSITIVE TYROSINE KINASE INHIBITOR AXITINIB IN HUMAN PLASMA.JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. VOL. 877. ISSUE 32. P. 4090 -4096 | 21 | 66% | 12 |
| 8 | MAHAJAN, AA , MINIYAR, PB , PATIL, AS , WAGHMARE, RU , PATIL, JJ , MOHANRAJ, K , TIWARI, RN , (2015) SEPARATION, IDENTIFICATION, AND CHARACTERIZATION OF DEGRADATION PRODUCTS OF ERLOTINIB HYDROCHLORIDE UNDER ICH-RECOMMENDED STRESS CONDITIONS BY LC, LC-MS/TOF.JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES. VOL. 38. ISSUE 5. P. 629 -639 | 17 | 68% | 0 |
| 9 | YILMAZ, EM , AYDOGMUS, Z , ABOUL-ENEIN, HY , (2016) DETERMINATION OF NILOTINIB IN SPIKED PLASMA, URINE, AND CAPSULES BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY WITH FLUORIMETRIC DETECTION.ACTA CHROMATOGRAPHICA. VOL. 28. ISSUE 3. P. 313 -331 | 13 | 81% | 0 |
| 10 | LANKHEET, NAG , HILLEBRAND, MJX , ROSING, H , SCHELLENS, JHM , BEIJNEN, JH , HUITEMA, ADR , (2013) METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTIFICATION OF DASATINIB, ERLOTINIB, GEFITINIB, IMATINIB, LAPATINIB, NILOTINIB, SORAFENIB AND SUNITINIB IN HUMAN PLASMA BY LIQUID CHROMATOGRAPHY COUPLED WITH TANDEM MASS SPECTROMETRY.BIOMEDICAL CHROMATOGRAPHY. VOL. 27. ISSUE 4. P. 466-476 | 17 | 52% | 47 |
Classes with closest relation at Level 1 |